Select Scientific Accomplishments

Selected Publications

Funding received from the UWCCC Cancer Center Support Grant (CCSG) for published research, including the use of UWCCC Shared Resources to generate or analyze data, or conduct clinical trials, needs to reference the UWCCC. See Acknowledging UWCCC in Publications, Posters, and Presentations.

View the UW Drug Development Core (DDC) page for more information on other UW–Madison laboratory facilities that provide state-of-the-art instrumentation and expert scientific staff.

Scribano CM, Wan J, Esbona K, Tucker JB, Lasek A, Zhou AS, Zasadil LM, Molini R, Fitzgerald J, Lager AM, Laffin JJ, Correia-Staudt K, Wisinski KB, Tevaarwerk AJ, O’Regan R, McGregor SM, Fowler AM, Chappell RJ, Bugni TS, Burkard ME, Weaver BA. Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel. Sci Transl Med. 2021 Sep 8;13(610):eabd4811. doi: 10.1126/scitranslmed.abd4811. Epub 2021 Sep 8. PMID: 34516829.

Jarrard D, Filon M, Huang W, Havighurst T, DeShong K, Kim K, Konety BR, Saltzstein D, Mukhtar H, Wollmer B, Suen C, House MG, Parnes HL, Bailey HH. A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance. Prostate. 2021 Jan;81(1):41-49. doi: 10.1002/pros.24076. Epub 2020 Oct 23. PMID: 33095939.

Kolesar JM, Andrews S, Green H, Havighurst TC, Wollmer BW, DeShong K, Laux DE, Krontiras H, Muccio DD, Kim K, Grubbs CJ, House MG, Parnes HL, Heckman-Stoddard BM, Bailey HH. A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers. Cancer Prev Res (Phila). 2019 Dec;12(12):903-912. doi: 10.1158/1940-6207.CAPR-19-0310. Epub 2019 Sep 4. PMID: 31484659; PMCID: PMC7008944.

Rampurwala M, Wisinski KB, Burkard ME, Ehsani S, O’Regan RM, Carmichael L, Kim K, Kolesar J, Tevaarwerk AJ. Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. Investigational new drugs. 2017;35(1):87-94. Epub 2016/11/09. doi: 10.1007/s10637-016-0403-2. PubMed PMID: 27826831.

Tomoda K, Tam YT, Cho H, Buehler D, Kozak KR, Kwon GS. Triolimus: A Multi-Drug Loaded Polymeric Micelle Containing Paclitaxel, 17-AAG, and Rapamycin as a Novel Radiosensitizer. Macromolecular bioscience. 2017;17(1). Epub 2016/07/02. doi: 10.1002/mabi.201600194. PubMed PMID: 27365266; PMCID: PMC5320892.

Bruce JY, LoRusso PM, Goncalves PH, Heath EI, Sadowski E, Shalinsky DR, Zhang Y, Traynor AM, Breazna A, Ricart AD, Tortorici M, Liu G. A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2016;77(3):527-38. Epub 2016/01/23. doi: 10.1007/s00280-016-2958-1. PubMed PMID: 26791870.

Deming DA, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Eickhoff JC, Kolesar JM, Fioravanti S, Greten TF, Compton K, Doyle AG, Wilding G, Duffy A, Liu G. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Investigational new drugs. 2016;34(2):168-75. Epub 2015/12/17. doi: 10.1007/s10637-015-0314-7. PubMed PMID: 26666244; PMCID: PMC4788533.

Gee JR, Saltzstein DR, Messing E, Kim K, Kolesar J, Huang W, Havighurst TC, Harris L, Wollmer BW, Jarrard D, House M, Parnes H, Bailey HH. Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP). 2016;25(4):312-20. Epub 2015/08/28. doi: 10.1097/cej.0000000000000189. PubMed PMID: 26313229.

Ivashko IN, Kolesar JM. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2016;73(4):193-201. Epub 2016/02/05. doi: 10.2146/ajhp140768. PubMed PMID: 26843495.

Jarrard D, Konety B, Huang W, Downs T, Kolesar J, Kim KM, Havighurst T, Slaton J, House MG, Parnes HL, Bailey HH. Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy. American journal of clinical and experimental urology. 2016;4(2):17-27. Epub 2016/10/22. PubMed PMID: 27766277; PMCID: PMC5069272.

Kujak C, Kolesar JM. Treatment of chronic myelogenous leukemia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2016;73(3):113-20. Epub 2016/01/23. doi: 10.2146/ajhp140686. PubMed PMID: 26796903.

Kyriakopoulos CE, Braden AM, Kolesar JM, Eickhoff JC, Bailey HH, Heideman J, Liu G, Wisinski KB. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. Investigational new drugs. 2016. Epub 2016/12/23. doi: 10.1007/s10637-016-0418-8. PubMed PMID: 28004284.

Kyriakopoulos CE, Heath EI, Eickhoff JC, Kolesar J, Yayehyirad M, Moll T, Wilding G, Liu G. A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer. Investigational new drugs. 2016;34(2):225-30. Epub 2016/03/01. doi: 10.1007/s10637-016-0334-y. PubMed PMID: 26924129.

Munroe M, Kolesar J. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2016;73(14):1037-41. Epub 2016/07/08. doi: 10.2146/ajhp150550. PubMed PMID: 27385701.

Scarpelli M, Bruce JY, Carmichael L, Eickhoff J, Kolesar J, Perlman S, Jeraj R, Liu G. 18F-FLT PET/CT imaging in patients with advanced solid malignancies treated with axitinib on an intermittent dosing regimen. Cancer chemotherapy and pharmacology. 2016;78(6):1245-52. Epub 2016/11/07. doi: 10.1007/s00280-016-3183-7. PubMed PMID: 27817059; PMCID: PMC5209788.

Sippy R, Kolesar JM, Darst BF, Engelman CD. Prioritization of family member sequencing for the detection of rare variants. BMC proceedings. 2016;10(Suppl 7):227-31. Epub 2016/12/17. doi: 10.1186/s12919-016-0035-8. PubMed PMID: 27980641; PMCID: PMC5133500.

Walko C, Kiel PJ, Kolesar J. Precision medicine in oncology: New practice models and roles for oncology pharmacists. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2016;73(23):1935-42. Epub 2016/11/20. doi: 10.2146/ajhp160211. PubMed PMID: 27864201.

Wisinski KB, Tevaarwerk AJ, Burkard ME, Rampurwala M, Eickhoff J, Bell MC, Kolesar JM, Flynn C, Liu G. Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016;22(11):2659-67. Epub 2016/03/31. doi: 10.1158/1078-0432.ccr-15-2365. PubMed PMID: 27026198; PMCID: PMC4891227.

Bruce JY, Scully PC, Carmichael LL, Eickhoff JC, Perlman SB, Kolesar JM, Heideman JL, Jeraj R, Liu G. Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3’deoxy-3’fluoro-L-thymidine positron emission tomography/computed tomography. Cancer chemotherapy and pharmacology. 2015;76(1):187-95. Epub 2015/05/30. doi: 10.1007/s00280-015-2779-7. PubMed PMID: 26021741; PMCID: PMC4499265.

Croegaert K, Kolesar JM. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2015;72(17):1456-62. Epub 2015/08/22. doi: 10.2146/ajhp140836. PubMed PMID: 26294238.

Deming D, Uboha N, Zafar SY, Rosenberg S, Bassetti M, Glasgow S, Borden EC, Lubner S. Adjuvant Chemotherapy for Stage II Rectal Cancer. Seminars in oncology. 2015;42(6):e99-107. Epub 2015/11/29. doi: 10.1053/j.seminoncol.2015.09.033. PubMed PMID: 26615141.

Engle JA, Kolesar JM. Importance of ethnicity and smoking status in EGFR gene testing in lung cancers. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2015;72(9):686-7. Epub 2015/04/16. doi: 10.2146/ajhp150001. PubMed PMID: 25873612.

Hanna NH, Dahlberg SE, Kolesar JM, Aggarwal C, Hirsch FR, Ramalingam SS, Schiller JH. Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). Cancer. 2015;121(13):2253-61. Epub 2015/03/06. doi: 10.1002/cncr.29308. PubMed PMID: 25740387; PMCID: PMC4560671.

Kolesar JM, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Kim K, Tangrea JA, Parnes HL, House MG, Gee J, Messing E, Bailey HH. Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2015;21(2):128-31. Epub 2014/03/20. doi: 10.1177/1078155214528552. PubMed PMID: 24642450; PMCID: PMC4261043.

LoConte NK, Razak AR, Ivy P, Tevaarwerk A, Leverence R, Kolesar J, Siu L, Lubner SJ, Mulkerin DL, Schelman WR, Deming DA, Holen KD, Carmichael L, Eickhoff J, Liu G. A multicenter phase 1 study of gamma -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Investigational new drugs. 2015;33(1):169-76. Epub 2014/10/17. doi: 10.1007/s10637-014-0166-6. PubMed PMID: 25318436; PMCID: PMC4297251.

Rastegar-Mojarad M, Ye Z, Kolesar JM, Hebbring SJ, Lin SM. Opportunities for drug repositioning from phenome-wide association studies. Nature biotechnology. 2015;33(4):342-5. Epub 2015/04/08. doi: 10.1038/nbt.3183. PubMed PMID: 25850054.

Rounds A, Kolesar J. Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2015;72(21):1851-5. Epub 2015/10/23. doi: 10.2146/ajhp150235. PubMed PMID: 26490818.

Tran NH, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Clipson L, Matkowskyj KA, Deming DA. Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Therapeutic advances in medical oncology. 2015;7(5):252-62. Epub 2015/09/04. doi: 10.1177/1758834015591952. PubMed PMID: 26327923; PMCID: PMC4543854.

Wisinski KB, Cantu CA, Eickhoff J, Osterby K, Tevaarwerk AJ, Heideman J, Liu G, Wilding G, Johnston S, Kolesar JM. Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2015;72(11):958-65. Epub 2015/05/20. doi: 10.2146/ajhp140591. PubMed PMID: 25987691; PMCID: PMC4510955.

Wisinski KB, Ledesma WM, Kolesar J, Wilding G, Liu G, Douglas J, Traynor AM, Albertini M, Mulkerin D, Bailey HH. A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1alpha,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2015;21(6):416-24. Epub 2014/07/06. doi: 10.1177/1078155214541572. PubMed PMID: 24986793; PMCID: PMC4281509.

Bruce JY, Kolesar JM, Hammers H, Stein MN, Carmichael L, Eickhoff J, Johnston SA, Binger KA, Heideman JL, Perlman SB, Jeraj R, Liu G. A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies. Cancer chemotherapy and pharmacology. 2014;73(3):485-93. Epub 2014/01/15. doi: 10.1007/s00280-013-2373-9. PubMed PMID: 24414551; PMCID: PMC4200479.

Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, Schelman WR. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Investigational new drugs. 2014;32(2):323-9. Epub 2013/10/12. doi: 10.1007/s10637-013-0035-8. PubMed PMID: 24114123; PMCID: PMC3949160.

Engle JA, Kolesar JM. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2014;71(22):1933-8. Epub 2014/10/29. doi: 10.2146/ajhp130654. PubMed PMID: 25349236.

Grudzinski JJ, Titz B, Kozak K, Clarke W, Allen E, Trembath L, Stabin M, Marshall J, Cho SY, Wong TZ, Mortimer J, Weichert JP. A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety. PloS one. 2014;9(11):e111652. Epub 2014/11/18. doi: 10.1371/journal.pone.0111652. PubMed PMID: 25402488; PMCID: PMC4234270.

Kirschling RJ, Johnson PH, Huie MS, Wims ME, Larson MM, Hernan HR, Traynor AM. Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. Investigational new drugs. 2014;32(1):195-9. Epub 2013/06/04. doi: 10.1007/s10637-013-9980-5. PubMed PMID: 23728919; PMCID: PMC4310688.

Kolesar JM, Eickhoff J, Vermeulen LC. Serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting: therapeutically equivalent or meaningfully different? American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2014;71(6):507-10. Epub 2014/03/05. doi: 10.2146/ajhp130653. PubMed PMID: 24589542; PMCID: PMC4158452.

Piccolo J, Kolesar JM. Prevention and treatment of chemotherapy-induced peripheral neuropathy. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2014;71(1):19-25. Epub 2013/12/20. doi: 10.2146/ajhp130126. PubMed PMID: 24352178.

Schelman WR, Mohammed TA, Traynor AM, Kolesar JM, Marnocha RM, Eickhoff J, Keppen M, Alberti DB, Wilding G, Takebe N, Liu G. A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Investigational new drugs. 2014;32(2):295-302. Epub 2013/07/19. doi: 10.1007/s10637-013-9999-7. PubMed PMID: 23860642; PMCID: PMC3895103.

Zasadil LM, Andersen KA, Yeum D, Rocque GB, Wilke LG, Tevaarwerk AJ, Raines RT, Burkard ME, Weaver BA. Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Science translational medicine. 2014;6(229):229ra43. Epub 2014/03/29. doi: 10.1126/scitranslmed.3007965. PubMed PMID: 24670687; PMCID: PMC4176609.

Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, Burtness B, Forastiere AA. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(11):1405-14. Epub 2013/03/06. doi: 10.1200/jco.2012.45.4272. PubMed PMID: 23460714; PMCID: PMC3612594.

Banaszynski M, Kolesar JM. Vemurafenib and ipilimumab: new agents for metastatic melanoma. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013;70(14):1205-10. Epub 2013/07/04. doi: 10.2146/ajhp120260. PubMed PMID: 23820456.

Gee J, Bailey H, Kim K, Kolesar J, Havighurst T, Tutsch KD, See W, Cohen MB, Street N, Levan L, Jarrard D, Wilding G. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1alpha-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. The Prostate. 2013;73(9):970-8. Epub 2013/01/22. doi: 10.1002/pros.22644. PubMed PMID: 23335089; PMCID: PMC3755376.

Greenwald DR, Li H, Luger SM, Go RS, King D, Patel T, Gascoyne RD, Kolesar J, Kahl BS, Horning S. A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404). Journal of hematology & oncology. 2013;6:46. Epub 2013/07/09. doi: 10.1186/1756-8722-6-46. PubMed PMID: 23829878; PMCID: PMC3716977.

Kolesar JM, Traynor AM, Holen KD, Hoang T, Seo S, Kim K, Alberti D, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH, Schelman WR. Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes. Cancer chemotherapy and pharmacology. 2013;72(3):661-7. Epub 2013/08/02. doi: 10.1007/s00280-013-2242-6. PubMed PMID: 23903894; PMCID: PMC3926898.

Kolesar JM, Vermeulen L. Assays for biological agents. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013;70(13):1101. Epub 2013/06/21. doi: 10.2146/ajhp130128. PubMed PMID: 23784155.

Liu G, Chen YH, Kolesar J, Huang W, Dipaola R, Pins M, Carducci M, Stein M, Bubley GJ, Wilding G. Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urologic oncology. 2013;31(2):211-8. Epub 2011/07/26. doi: 10.1016/j.urolonc.2011.01.002. PubMed PMID: 21784672; PMCID: PMC3223557.

LoConte NK, Holen KD, Schelman WR, Mulkerin DL, Deming DA, Hernan HR, Traynor AM, Goggins T, Groteluschen D, Oettel K, Robinson E, Lubner SJ. A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Investigational new drugs. 2013;31(4):943-8. Epub 2012/12/25. doi: 10.1007/s10637-012-9916-5. PubMed PMID: 23263993; PMCID: PMC4199231.

Poggi L, Kolesar JM. Vismodegib for the treatment of basal cell skin cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013;70(12):1033-8. Epub 2013/05/31. doi: 10.2146/ajhp120311. PubMed PMID: 23719880.

Sachidanandam K, Gayle AA, Robins HI, Kolesar JM. Unexpected doxorubicin-mediated cardiotoxicity in sisters: possible role of polymorphisms in histamine n-methyl transferase. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2013;19(3):269-72. Epub 2012/11/17. doi: 10.1177/1078155212461022. PubMed PMID: 23154571; PMCID: PMC3998823.

Simondsen K, Kolesar J. New treatment options for castration-resistant prostate cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013;70(10):856-65. Epub 2013/05/04. doi: 10.2146/ajhp110586. PubMed PMID: 23640346.

Timm A, Kolesar JM. Crizotinib for the treatment of non-small-cell lung cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013;70(11):943-7. Epub 2013/05/21. doi: 10.2146/ajhp120261. PubMed PMID: 23686600.

Ton GN, Banaszynski ME, Kolesar JM. Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013;70(10):849-55. Epub 2013/05/04. doi: 10.2146/ajhp120253. PubMed PMID: 23640345.

Zhang Y, Vermeulen LC, Kolesar JM. Stability of stock and diluted rituximab. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013;70(5):436-8. Epub 2013/02/16. doi: 10.2146/ajhp120035. PubMed PMID: 23413167; PMCID: PMC3987107.

Gorden KJ, Mesbah P, Kolesar JM. EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2012;18(2):245-9. Epub 2011/07/08. doi: 10.1177/1078155211408373. PubMed PMID: 21733906.

Hoang T, Campbell TC, Zhang C, Kim K, Kolesar JM, Oettel KR, Blank JH, Robinson EG, Ahuja HG,

Ikeda R, Vermeulen LC, Lau E, Jiang Z, Saha S, Reichelderfer M, Kolesar JM. Stability of infliximab in polyvinyl chloride bags. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2012;69(17):1509-12. Epub 2012/08/18. doi: 10.2146/ajhp100116. PubMed PMID: 22899746; PMCID: PMC3987119.

Messing E, Gee JR, Saltzstein DR, Kim K, diSant’Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, House M, Busby JE, Hohl R, Bailey H. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer prevention research (Philadelphia, Pa). 2012;5(4):621-30. Epub 2012/02/02. doi: 10.1158/1940-6207.capr-11-0455. PubMed PMID: 22293631; PMCID: PMC3324663.

Pearson R, Kolesar JM. Targeted therapy for NSCLC: ALK inhibition. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2012;18(2):271-4. Epub 2011/08/17. doi: 10.1177/1078155211417477. PubMed PMID: 21844131.

Richardson PG, Eng C, Kolesar J, Hideshima T, Anderson KC. Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert opinion on drug metabolism & toxicology. 2012;8(5):623-33. Epub 2012/04/20. doi: 10.1517/17425255.2012.681376. PubMed PMID: 22512706; PMCID: PMC4467022.

Shin HC, Cho H, Lai TC, Kozak KR, Kolesar JM, Kwon GS. Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin. Journal of controlled release : official journal of the Controlled Release Society. 2012;163(1):93-9. Epub 2012/05/03. doi: 10.1016/j.jconrel.2012.04.024. PubMed PMID: 22549011; PMCID: PMC3422612.

Simondsen KA, Kolesar JM. Lenalidomide-induced elevated bilirubin. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2012;18(4):402-5. Epub 2012/03/13. doi: 10.1177/1078155212439492. PubMed PMID: 22407059.

Zhang Y, Simondsen K, Kolesar JM. Exemestane for primary prevention of breast cancer in postmenopausal women. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2012;69(16):1384-8. Epub 2012/08/03. doi: 10.2146/ajhp110585. PubMed PMID: 22855103.

Ramalingam SS, Lee JW, Belani CP, Aisner SC, Kolesar J, Howe C, Velasco MR, Schiller JH. Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504). J Clin Oncol. 2011;29(13):1709-14. PMCID: PMC3107763.

Liu G, Jeraj R, Vanderhoek M, Perlman S, Kolesar J, Harrison M, Simoncic U, Eickhoff J, Carmichael L, Chao B, Marnocha R, Ivy P, Wilding G. Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clin Cancer Res. 2011;17(24):7634-44. PMCID: PMC3243764.
Dennie TW, Fleming RA, Bowen CJ, Dar MM, Alberti D, Oliver K, Loconte N, Mulkerin D, Holen KD. A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors. Clin Colorectal Cancer. 2011;10(1):57-62.
Tevaarwerk A, Wilding G, Eickhoff J, Chappell R, Sidor C, Arnott J, Bailey H, Schelman W, Liu G. Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Invest New Drugs. 2011. PMCID: PMC3139017.
Cetnar J, Wilding G, McNeel D, Loconte NK, McFarland TA, Eickhoff J, Liu G. A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urol Oncol. 2011.
Kolesar JM, Sachidanandam K, Schelman WR, Eickhoff J, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE. Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance. Exp Ther Med. 2011;2(1):119-23. PMCID: PMC3046871.
Heath EI, Blumenschein GR, Jr., Cohen RB, Lorusso PM, Loconte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemother Pharmacol. 2011;68(3):703-12.
Kolesar J, Brundage RC, Pomplun M, Alberti D, Holen K, Traynor A, Ivy P, Wilding G. Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine(R)) in cancer patients. Cancer Chemother Pharmacol. 2011;67(2):393-400. PMCID: PMC3059107.
Rathkopf D, Liu G, Carducci MA, Eisenberger MA, Anand A, Morris MJ, Slovin SF, Sasaki Y, Takahashi S, Ozono S, Fung NK, Cheng S, Gan J, Gottardis M, Obermeier MT, Reddy J, Zhang S, Vakkalagadda BJ, Alland L, Wilding G, Scher HI, Prostate Cancer Clinical Trials C. Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clin Cancer Res. 2011;17(4):880-7. PMCID: PMC3070382.
Choi BS, Alberti DB, Schelman WR, Kolesar JM, Thomas JP, Marnocha R, Eickhoff JC, Ivy SP, Wilding G, Holen KD. The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. Cancer Chemother Pharmacol. 2010;66(5):973-80. PMCID: PMC2921466.
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM, Children’s Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324-34. PMCID: PMC3086629.
Wernimont SA, Simonson WT, Greer PA, Seroogy CM, Huttenlocher A. Calpain 4 is not necessary for LFA-1-mediated function in CD4+ T cells. PLoS One. 2010;5(5):e10513. PMCID: PMC2866319.
Wang J, Liu Y, Li Z, Du J, Ryu MJ, Taylor PR, Fleming MD, Young KH, Pitot H, Zhang J. Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood. 2010;116(26):5991-6002. PMCID: PMC3031386.
Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children’s Oncology Group (COG) phase II study. J Clin Oncol. 2010;28(33):4969-75. PMCID: PMC3020698.
Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, Philip PA, Picus J, Yong WP, Horvath L, Van Hazel G, Erlichman CE, Holen KD.
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.
J Clin Oncol. 2010;28(21):3491-7. PMCID: PMC2917213.
Kolesar JM, Hoel R, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Krontiras H, Brouillette W, Muccio D, Kim K, Grubbs CJ, Bailey H. A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers. Cancer Prev Res. 2010;3(12):1565-70. PMCID: PMC3204611.
Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the department of defense prostate cancer clinical trials consortium. Cancer. 2010.
Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010;70(23):9554-61. PMCID: PMC2999644.
Bailey HH, Kim K, Verma AK, Sielaff K, Larson PO, Snow S, Lenaghan T, Viner JL, Douglas J, Dreckschmidt NE, Hamielec M, Pomplun M, Sharata HH, Puchalsky D, Berg ER, Havighurst TC, Carbone PP. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res (Phila). 2010;3(1):35-47. PMCID: PMC2804946.
Tevaarwerk AJ, Holen KD, Alberti DB, Sidor C, Arnott J, Quon C, Wilding G, Liu G. Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin Cancer Res. 2009;15(4):1460-5. PMCID: PMC2892631.
Schelman WR, Morgan-Meadows S, Marnocha R, Lee F, Eickhoff J, Huang W, Pomplun M, Jiang Z, Alberti D, Kolesar JM, Ivy P, Wilding G, Traynor AM. A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009;63(6):1147-56. PMCID: PMC3050713.
Kolesar J, Huang W, Eickhoff J, Hahn K, Alberti D, Attia S, Schelman W, Holen K, Traynor A, Ivy P, Wilding G. Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. Cancer Chemother Pharmacol. 2009;64(1):79-86. PMCID: PMC3043989.
Hank JA, Gan J, Ryu H, Ostendorf A, Stauder MC, Sternberg A, Albertini M, Lo KM, Gillies SD, Eickhoff J, Sondel PM. Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma. Clin Cancer Res. 2009;15(18):5923-30. PMCID: PMC2745522.
Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, Pili R, Zwiebel J, Scher H, Hussain M. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer. 2009;115(23):5541-9. PMCID: PMC2917101.
Basu HS, Thompson TA, Church DR, Clower CC, Mehraein-Ghomi F, Amlong CA, Martin CT, Woster PM, Lindstrom MJ, Wilding G. A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2009;69(19):7689-95. PMCID: PMC2756327.
Argiris A, Buchanan A, Brockstein B, Kolesar J, Ghebremichael M, Pins M, Hahn K, Axelrod R, Forastiere A. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group. Cancer. 2009;115(19):4504-13. PMCID: PMC2749918.
LoConte NK, Thomas JP, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, Kolesar J. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. Cancer Chemother Pharmacol. 2008;63(1):109-15.
Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, Huang W, Eickhoff J, Erlichman C, Holen KD. A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs. 2008;26(4):369-79.
Ricart AD, Tolcher AW, Liu G, Holen K, Schwartz G, Albertini M, Weiss G, Yazji S, Ng C, Wilding G. Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res. 2008;14(23):7924-9. NIHMSID: NIHMS340779
Liu G, Kolesar J, McNeel DG, Leith C, Schell K, Eickhoff J, Lee F, Traynor A, Marnocha R, Alberti D, Zwiebel J, Wilding G. http://www.ncbi.nlm.nih.gov/pubmed/?term=PMC2950700 target=”_blank”  Clin Cancer Res. 2008;14(9):2732-9. PMCID: PMC2950700.
Kolesar JM, Schelman WR, Geiger PG, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE. Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine. J Inorg Biochem. 2008;102(4):693-8. PMCID: PMC2390869.
Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, Albertini MR, O’Dwyer PJ. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res. 2008;14(15):4836-42.
Chaiswing L, Zhong W, Cullen JJ, Oberley LW, Oberley TD. Extracellular redox state regulates features associated with prostate cancer cell invasion. Cancer Res. 2008;68(14):5820-6.
Attia S, Eickhoff J, Wilding G, McNeel D, Blank J, Ahuja H, Jumonville A, Eastman M, Shevrin D, Glode M, Alberti D, Staab MJ, Horvath D, Straus J, Marnocha R, Liu G. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res. 2008;14(8):2437-43.
Takimoto CH, Graham MA, Lockwood G, Ng CM, Goetz A, Greenslade D, Remick SC, Sharma S, Mani S, Ramanathan RK, Synold TW, Doroshow JH, Hamilton A, Mulkerin DL, Ivy P, Egorin MJ, Grem JL. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res. 2007;13(16):4832-9.
Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, Mulkerin DL, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Kaufman BM, Ivy P, National Cancer Institute Organ Dysfunction Working Group study. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2007;13(12):3660-6.
Zhang D, Pier T, McNeel DG, Wilding G, Friedl A. Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels – a pharmacodynamic study. Invest New Drugs. 2007;25(1):49-55.
MacKenzie DA, Schartner J, Lin J, Timmel A, Jennens-Clough M, Fathman CG, Seroogy CM. GRAIL is up-regulated in CD4+ CD25+ T regulatory cells and is sufficient for conversion of T cells to a regulatory phenotype. J Biol Chem. 2007;282(13):9696-702.